Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed COO
Employment agrmnt
|
|
TCR2 THERAPEUTICS INC. (TCRR)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 03/06/2023 |
8-K
| Amended existing or entered into new employment agreement with an officer|
Docs:
|
"Exhibit 2.1    EXECUTION VERSION   AGREEMENT AND PLAN OF MERGER   BY AND AmONG   Adaptimmune therapeutics plc,   cm Merger sub, Inc.   AND   tcr 2 therapeutics inc.",
"Agreement”) is made and entered into as of March 5, 2023 , by and among Adaptimmune Therapeutics PLC , a public company limited by shares incorporated in England and Wales, TCR 2 Therapeutics Inc. , a Delaware corporation and [STOCKHOLDER] . Each of Parent, the Company and the Stockholder are sometimes referred to as a “Party” and collectively as the “Parties",
"VOTING AND SUPPORT AGREEMENT   This Voting and Support Agreement is made and entered into as of March 5, 2023 , by and among  Adaptimmune Therapeutics PLC , a public company limited by shares incorporated in England and Wales,  TCR 2 Therapeutics Inc. , a Delaware corporation and  [SHAREHOLDER] . Each of Parent, the Company and the Shareholder are sometimes referred to as a “Party” and collectively as the “Parties”. Capitalized terms used but not defined herein have the meanings ascribed to such terms in the Merger Agreement .   RECITALS   A.              Concurrently with the execution and delivery of this Agreement, Parent, the Company and CM Merger Sub, Inc...",
"FIRST AMENDMENT TO EMPLOYMENT AGREEMENT",
"Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors Compelling clinical data with clear paths to products and multiple near-term value-creating catalysts Complementary technology platforms designed to treat solid tumors which represents a substantial market opportunity largely unaddressed by cell therapies Following closing of the transaction, cash runway extended into 2026 Following the all-stock transaction, currently expected to close in Q2 2023, Adaptimmune shareholders will own ~75% and TCR² Therapeutics stockholders will own ~25% of the combined company Companies to host a joint Webcast today, March 6, 2023, at 8:00 a.m. EST",
"of Section 27 A of the Securities Act of 1933",
"significant operational advantages" |
|
|
|